probiotics and polycistic ovary syndrome women

Effect of probiotic supplementation on ß-cell pancreatic function indices, lipid profile, inflammatory indices and blood pressure in polycystic ovarian syndrome women

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2013081111763N11

Enrollment

Registered

2013-08-25

Start date

2013-06-22

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Polycystic Ovarian Syndrome. Sclerocystic ovary syndrome

Interventions

Intervention 1: Probiotic Familact, 500 miligrams capsules, once a day (with lunch), for 60 days. Intervention 2: Placebo.

Treatment - Drugs

Placebo

Probiotic Familact, 500 miligrams capsules, once a day (with lunch), for 60 days.

Eligibility

Sex/Gender

Female

Age

15 Years to 40 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Women with polycystic ovarian syndrome (based on Rotterdam criteria), aged 15 to 40, lack of smoking or drinking alcohol, lack of chronic heart, kidney, liver, lung or pancreatic specially endocardic diseases, thyroid disorder, small bowel syndrome, autoimmune disease, lack of allergy to probiotic capsules or placebo, not use of chemotherapy drugs (tamoxifen), corticosteroid (insulin injection, statins, diuretics) antibiotic and multivitamin mineral supplements and omega-3. Exclusion criteria: incidence of diseases mentioned above, use of multivitamin mineral supplement.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Fasting Blood Glucose. Timepoint: The first day of the study and the last day of 8th week. Method of measurement: Colorimetry.;Total serum cholestrol. Timepoint: The first day of the study and the last day of 8th week. Method of measurement: Enzymatic assay with autoanalyser.;Serum triglycerides. Timepoint: The first day of the study and the last day of 8th week. Method of measurement: Enzymatic assay with autoanalyser.;Serum low density lipoprotein. Timepoint: The first day of the study and the last day of 8th week. Method of measurement: Enzymatic assay with autoanalyser.;Serum High density lipoprotein. Timepoint: The first day of the study and the last day of 8th week. Method of measurement: Enzymatic assay with autoanalyser.;High sensitive C- Reactive Protein. Timepoint: The first day of the study and the last day of 8th week. Method of measurement: Turbidimetric Method.;Serum Insulin. Timepoint: The first day of the study and the last day of 8th week. Method of measurement: Enzyme-Linked Immunosorbent Assay (ELISA)?µU/mL.;HOMA-IR. Timepoint: The first day of the study and the last day of 8th week. Method of measurement: Formula.	—

Measure

Time frame

Fasting Blood Glucose. Timepoint: The first day of the study and the last day of 8th week. Method of measurement: Colorimetry.;Total serum cholestrol. Timepoint: The first day of the study and the last day of 8th week. Method of measurement: Enzymatic assay with autoanalyser.;Serum triglycerides. Timepoint: The first day of the study and the last day of 8th week. Method of measurement: Enzymatic assay with autoanalyser.;Serum low density lipoprotein. Timepoint: The first day of the study and the last day of 8th week. Method of measurement: Enzymatic assay with autoanalyser.;Serum High density lipoprotein. Timepoint: The first day of the study and the last day of 8th week. Method of measurement: Enzymatic assay with autoanalyser.;High sensitive C- Reactive Protein. Timepoint: The first day of the study and the last day of 8th week. Method of measurement: Turbidimetric Method.;Serum Insulin. Timepoint: The first day of the study and the last day of 8th week. Method of measurement: Enzyme-Linked Immunosorbent Assay (ELISA)?µU/mL.;HOMA-IR. Timepoint: The first day of the study and the last day of 8th week. Method of measurement: Formula.

—

Secondary

Measure	Time frame
Blood pressure. Timepoint: The first day of the study and the last day of 8th week. Method of measurement: mmHg, sphygmomanometer.;Weight. Timepoint: The first day of the study and the last day of 8th week. Method of measurement: Scale, Kilogram.;Height. Timepoint: The first day of the study. Method of measurement: Meter, Centimeter.;Body Mass Index. Timepoint: The first day of the study and the last day of 8th week. Method of measurement: kg/m2, Weight/Height square.;Waist Circumference. Timepoint: The first day of the study and the last day of 8th week. Method of measurement: meter,centimeter.	—

Measure

Time frame

Blood pressure. Timepoint: The first day of the study and the last day of 8th week. Method of measurement: mmHg, sphygmomanometer.;Weight. Timepoint: The first day of the study and the last day of 8th week. Method of measurement: Scale, Kilogram.;Height. Timepoint: The first day of the study. Method of measurement: Meter, Centimeter.;Body Mass Index. Timepoint: The first day of the study and the last day of 8th week. Method of measurement: kg/m2, Weight/Height square.;Waist Circumference. Timepoint: The first day of the study and the last day of 8th week. Method of measurement: meter,centimeter.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactTanaz Shoaei

Isfahan University Of Medical Sciences

shoaeit@ymail.com+98 31 1792 2110

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026